OTCPK:SHWG.F

Stock Analysis Report

Shandong Weigao Group Medical Polymer

Executive Summary

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China.

Snowflake

Fundamentals

Solid track record with excellent balance sheet and pays a dividend.


Similar Companies

Share Price & News

How has Shandong Weigao Group Medical Polymer's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:SHWG.F

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

n/a

OTCPK:SHWG.F

9.7%

US Medical Equipment

1.9%

US Market

No trading data on SHWG.F.

No trading data on SHWG.F.


Share holder returns

SHWG.FIndustryMarket
7 Day0%1.5%0.8%
30 Day0%0.7%3.4%
90 Day8.0%2.4%2.1%
1 Yearn/a10.6%9.7%4.2%1.9%
3 Yearn/a70.2%65.0%46.7%37.2%
5 Year-5.0%-5.0%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Shandong Weigao Group Medical Polymer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Shandong Weigao Group Medical Polymer undervalued based on future cash flows and its price relative to the stock market?

19.39x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Shandong Weigao Group Medical Polymer's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Shandong Weigao Group Medical Polymer's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Shandong Weigao Group Medical Polymer is good value based on earnings compared to the US Medical Equipment industry average.

Shandong Weigao Group Medical Polymer is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Shandong Weigao Group Medical Polymer is poor value based on expected growth next year.


Price Based on Value of Assets

Shandong Weigao Group Medical Polymer is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Shandong Weigao Group Medical Polymer expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

14.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Shandong Weigao Group Medical Polymer's revenue is expected to grow by 13.6% yearly, however this is not considered high growth (20% yearly).

Shandong Weigao Group Medical Polymer's earnings are expected to grow by 14.8% yearly, however this is not considered high growth (20% yearly).

Shandong Weigao Group Medical Polymer's revenue growth is expected to exceed the United States of America market average.

Shandong Weigao Group Medical Polymer's earnings growth is expected to exceed the United States of America market average.

Shandong Weigao Group Medical Polymer's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Shandong Weigao Group Medical Polymer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Shandong Weigao Group Medical Polymer performed over the past 5 years?

15.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Shandong Weigao Group Medical Polymer's year on year earnings growth rate has been positive over the past 5 years.

Shandong Weigao Group Medical Polymer's 1-year earnings growth exceeds its 5-year average (40.1% vs 15.1%)

Shandong Weigao Group Medical Polymer's earnings growth has exceeded the US Medical Equipment industry average in the past year (40.1% vs 28.9%).


Return on Equity

Shandong Weigao Group Medical Polymer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Shandong Weigao Group Medical Polymer used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Shandong Weigao Group Medical Polymer has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Shandong Weigao Group Medical Polymer's financial position?


Financial Position Analysis

Shandong Weigao Group Medical Polymer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Shandong Weigao Group Medical Polymer's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Shandong Weigao Group Medical Polymer's level of debt (34.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (2.9% vs 34.4% today).

Debt is well covered by operating cash flow (42.6%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 28.1x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2x debt.


Next Steps

Dividend

What is Shandong Weigao Group Medical Polymer's current dividend yield, its reliability and sustainability?

1.80%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Shandong Weigao Group Medical Polymer's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.43%).

Shandong Weigao Group Medical Polymer's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are thoroughly covered by earnings (7.5x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (3.6x coverage).


Next Steps

Management

What is the CEO of Shandong Weigao Group Medical Polymer's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Jing Long (44yo)

1.1yrs

Tenure

CN¥2,325,000

Compensation

Mr. Long Jing has been Chief Executive Officer and Executive Director of Shandong Weigao Group Medical Polymer Company Limited since August 29, 2018. Mr. Jing serves as a Vice-General Manager of Shandong W ...


CEO Compensation Analysis

Jing's remuneration is lower than average for companies of similar size in United States of America.

Jing's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.6yrs

Average Tenure

47yo

Average Age

The tenure for the Shandong Weigao Group Medical Polymer management team is about average.


Board Age and Tenure

7.9yrs

Average Tenure

57yo

Average Age

The tenure for the Shandong Weigao Group Medical Polymer board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Hua Wei Zhang (55yo)

    Chairman & Compliance Officer

    • Tenure: 3.5yrs
    • Compensation: CN¥2.31m
  • Phillis Wong (50yo)

    Company Secretary

    • Tenure: 13.3yrs
  • Hong Feng Ju (44yo)

    Vice-General Manager of the Production and Supply Chain

    • Tenure: 0yrs
  • Jian Bo Gong (51yo)

    Executive Director

    • Tenure: 6.5yrs
    • Compensation: CN¥10.89m
  • Jing Long (44yo)

    CEO & Executive Director

    • Tenure: 1.1yrs
    • Compensation: CN¥2.33m
  • Xue Feng Wu (41yo)

    Chief Financial Officer

    • Tenure: 2.6yrs

Board Members

  • Shu Hua Zhou (62yo)

    Non Executive Director

    • Tenure: 18.8yrs
  • Hua Wei Zhang (55yo)

    Chairman & Compliance Officer

    • Tenure: 3.5yrs
    • Compensation: CN¥2.31m
  • Yi Wang (59yo)

    Executive Director

    • Tenure: 18.8yrs
    • Compensation: CN¥1.27m
  • Xiao Yun Chen (45yo)

    Supervisor

    • Tenure: 0yrs
  • Dong Mei Bi (55yo)

    Chairman of the Board of Supervisors

    • Tenure: 0yrs
  • Ming Zhong Fu (68yo)

    Independent Non-Executive Director

    • Tenure: 7.9yrs
    • Compensation: CN¥108.00k
  • Jin Xia Wang (64yo)

    Independent Non-Executive Director

    • Tenure: 7.3yrs
    • Compensation: CN¥108.00k
  • Wai Hung Lo (59yo)

    Independent Non Executive Director

    • Tenure: 10.1yrs
    • Compensation: CN¥154.00k
  • Jian Bo Gong (51yo)

    Executive Director

    • Tenure: 6.5yrs
    • Compensation: CN¥10.89m
  • Jing Long (44yo)

    CEO & Executive Director

    • Tenure: 1.1yrs
    • Compensation: CN¥2.33m

Company Information

Shandong Weigao Group Medical Polymer Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shandong Weigao Group Medical Polymer Company Limited
  • Ticker: SHWG.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: HK$37.490b
  • Listing Market Cap: HK$4.793b
  • Shares outstanding: 4.52b
  • Website: https://www.weigaogroup.com

Number of Employees


Location

  • Shandong Weigao Group Medical Polymer Company Limited
  • Torch Hi-Tech Science Park
  • 18 Xingshan Road
  • Weihai
  • Shandong Province
  • 264210
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1066SEHK (The Stock Exchange of Hong Kong Ltd.)YesForeign Shares-Foreign ListedHKHKDFeb 2004
UK2DB (Deutsche Boerse AG)YesForeign Shares-Foreign ListedDEEURFeb 2004
SHWG.FOTCPK (Pink Sheets LLC)YesForeign Shares-Foreign ListedUSUSDFeb 2004
1066SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)YesForeign Shares-Foreign ListedHKHKDFeb 2004
1066SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)YesForeign Shares-Foreign ListedHKHKDFeb 2004
SHWG.YOTCPK (Pink Sheets LLC)ADS REP SHS HUSUSDNov 2010

Biography

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. The company operates thr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:21
End of Day Share Price2019/07/29 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.